{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0","upperLimit":"21.8","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Percentage of responses (if any) after crossover from the control arm to the combination arm will be evaluated qualitatively. This is includes complete and partial responses, and is different from Outcome Measure 8 below, which includes complete and partial responses as well as stable disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive temsirolimus IV over 30-60 minutes and cetuximab IV over 1-2 hours once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A (Cetuximab and Temsirolimus)"},{"description":"Patients receive temsirolimus as in Arm A. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over to Arm A.","id":"OG001","title":"Arm B (Temsirolimus)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Percentage of Responses After Crossover From Control Arm to the Combination Arm, Assessed According to RECIST","type":"SECONDARY","unitOfMeasure":"percentage of participants"}